PMID- 35832729
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2001-8525 (Print)
IS  - 2001-8525 (Electronic)
IS  - 2001-8525 (Linking)
VI  - 9
IP  - 1
DP  - 2022
TI  - Cellular mechanisms involved in the pathogenesis of airway remodeling in chronic 
      lung disease.
PG  - 2097377
LID - 10.1080/20018525.2022.2097377 [doi]
LID - 2097377
AB  - BACKGROUND: Airway epithelial cells and lung fibroblasts play an important role 
      in the development of chronic lung disease, but the exact mechanisms responsible 
      have not been clarified. Our objective was to investigate the involvement of 
      these cells in the inflammatory response associated to chronic lung disease. 
      METHODS: Human lung fibroblasts and airway epithelial cells were challenged with 
      Interleukin-1beta and hypoxia, and with inhibitory (simvastatin) stimuli of the 
      inflammatory response. Expression of markers of local inflammation ((IL-8, 
      monocyte chemoattractant protein-1 (MCP-1), factor-kappaB1 (NF-kappaB1)), systemic 
      inflammation ((C-reactive protein (CRP) and serum amyloid A (SAA)) and proteases 
      matrix metalloproteinase (MMP) 9 and 12 were assessed by PCR and ELISA. 
      Apoptosis/necrosis was analyzed by flow cytometry. RESULTS: Our results showed 
      that the lung fibroblasts had a higher expression of local and systemic 
      inflammation and protease activity markers when they were treated with IL-1beta 
      compared to airway epithelial cells. Under hypoxic conditions, we observed a 
      decrease in systemic inflammation in lung fibroblasts, which was further 
      attenuated by simvastatin. CONCLUSION: The lung fibroblasts seem to be the main 
      initially stimulated cells that could potentially trigger the inflammatory 
      response, and be responsible for the eventual onset of chronic lung disease. The 
      involvement of IL-1ss stimulation in systemic inflammatory and proteinase 
      imbalance biomarkers is higher in lung fibroblasts. Apoptosis is not a 
      predominant mechanism in these cells.
CI  - (c) 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & 
      Francis Group.
FAU - Arellano-Orden, E
AU  - Arellano-Orden E
AD  - Unidad Medico Quirurgica de Enfermedades Respiratorias, Instituto de Biomedicina 
      de Sevilla (IBIS), Hospital Universitario Virgen del Rocio/Universidad de 
      SevillaUnidad Medico Quirurgica de Enfermedades Respiratorias,Quirurgica, 
      Seville, Spain.
AD  - CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 
      Madrid, Spain.
FAU - Calero Acuna, C
AU  - Calero Acuna C
AD  - Unidad Medico Quirurgica de Enfermedades Respiratorias, Instituto de Biomedicina 
      de Sevilla (IBIS), Hospital Universitario Virgen del Rocio/Universidad de 
      SevillaUnidad Medico Quirurgica de Enfermedades Respiratorias,Quirurgica, 
      Seville, Spain.
AD  - CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 
      Madrid, Spain.
FAU - Sanchez-Lopez, V
AU  - Sanchez-Lopez V
AD  - Unidad Medico Quirurgica de Enfermedades Respiratorias, Instituto de Biomedicina 
      de Sevilla (IBIS), Hospital Universitario Virgen del Rocio/Universidad de 
      SevillaUnidad Medico Quirurgica de Enfermedades Respiratorias,Quirurgica, 
      Seville, Spain.
AD  - CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 
      Madrid, Spain.
FAU - Lopez Ramirez, C
AU  - Lopez Ramirez C
AD  - Unidad Medico Quirurgica de Enfermedades Respiratorias, Instituto de Biomedicina 
      de Sevilla (IBIS), Hospital Universitario Virgen del Rocio/Universidad de 
      SevillaUnidad Medico Quirurgica de Enfermedades Respiratorias,Quirurgica, 
      Seville, Spain.
AD  - CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 
      Madrid, Spain.
FAU - Otero-Candelera, R
AU  - Otero-Candelera R
AD  - Unidad Medico Quirurgica de Enfermedades Respiratorias, Instituto de Biomedicina 
      de Sevilla (IBIS), Hospital Universitario Virgen del Rocio/Universidad de 
      SevillaUnidad Medico Quirurgica de Enfermedades Respiratorias,Quirurgica, 
      Seville, Spain.
AD  - CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 
      Madrid, Spain.
FAU - Marin-Hinojosa, C
AU  - Marin-Hinojosa C
AD  - Unidad Medico Quirurgica de Enfermedades Respiratorias, Instituto de Biomedicina 
      de Sevilla (IBIS), Hospital Universitario Virgen del Rocio/Universidad de 
      SevillaUnidad Medico Quirurgica de Enfermedades Respiratorias,Quirurgica, 
      Seville, Spain.
AD  - CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 
      Madrid, Spain.
FAU - Lopez Campos, Jl
AU  - Lopez Campos J
AUID- ORCID: 0000-0003-1703-1367
AD  - Unidad Medico Quirurgica de Enfermedades Respiratorias, Instituto de Biomedicina 
      de Sevilla (IBIS), Hospital Universitario Virgen del Rocio/Universidad de 
      SevillaUnidad Medico Quirurgica de Enfermedades Respiratorias,Quirurgica, 
      Seville, Spain.
AD  - CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 
      Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20220708
PL  - United States
TA  - Eur Clin Respir J
JT  - European clinical respiratory journal
JID - 101662134
PMC - PMC9272929
OTO - NOTNLM
OT  - Chronic lung disease
OT  - human airway epithelial cells
OT  - human lung fibroblasts
OT  - inflammatory response
OT  - pathogenesis and simvastatin
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/07/15 06:00
MHDA- 2022/07/15 06:01
PMCR- 2022/07/08
CRDT- 2022/07/14 02:28
PHST- 2022/07/14 02:28 [entrez]
PHST- 2022/07/15 06:00 [pubmed]
PHST- 2022/07/15 06:01 [medline]
PHST- 2022/07/08 00:00 [pmc-release]
AID - 2097377 [pii]
AID - 10.1080/20018525.2022.2097377 [doi]
PST - epublish
SO  - Eur Clin Respir J. 2022 Jul 8;9(1):2097377. doi: 10.1080/20018525.2022.2097377. 
      eCollection 2022.